Literature DB >> 19371803

Bone histomorphometry in renal osteodystrophy.

Susan M Ott1.   

Abstract

On bone biopsies from patients with chronic kidney disease, measurements are made of the turnover, mineralization, and volume. Turnover depends on the bone formation rate and bone resorption rate; the former can be measured using tetracycline labelling. The osteoid width and bone apposition rate determine the mineralization rates. Bone volume includes both mineralized and unmineralized bone and is directly related to the porosity. Using these measurements, biopsies can be separated into the classic types of renal osteodystrophy: normal, adynamic, high-turnover, mixed, and osteomalacia. Fracture rates among these types are not consistent, but several studies have found high fracture rates with adynamic or osteomalacia. The bone density tests cannot distinguish between different types of bone histology.

Entities:  

Mesh:

Year:  2009        PMID: 19371803     DOI: 10.1016/j.semnephrol.2009.01.005

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  13 in total

1.  CKD-mineral and bone disorder: core curriculum 2011.

Authors:  Ranjani N Moorthi; Sharon M Moe
Journal:  Am J Kidney Dis       Date:  2011-10-21       Impact factor: 8.860

2.  Pediatric solid organ transplantation and osteoporosis: a descriptive study on bone histomorphometric findings.

Authors:  Inari S Tamminen; Helena Valta; Hannu Jalanko; Sari Salminen; Mervi K Mäyränpää; Hanna Isaksson; Heikki Kröger; Outi Mäkitie
Journal:  Pediatr Nephrol       Date:  2014-02-23       Impact factor: 3.714

3.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

4.  Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.

Authors:  Christopher L Newman; Neal X Chen; Eric Smith; Mark Smith; Drew Brown; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2015-04-17       Impact factor: 4.398

5.  Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.

Authors:  M R Allen; C L Newman; N Chen; M Granke; J S Nyman; S M Moe
Journal:  Osteoporos Int       Date:  2014-12-03       Impact factor: 4.507

Review 6.  Therapy for patients with CKD and low bone mineral density.

Authors:  Susan M Ott
Journal:  Nat Rev Nephrol       Date:  2013-10-08       Impact factor: 28.314

7.  Redefining Human Vitamin D Sufficiency: Back to the Basics.

Authors:  John S Adams; Jonathan Ramin; Brandon Rafison; Charles Windon; Annika Windon; Philip T Liu
Journal:  Bone Res       Date:  2013       Impact factor: 13.567

8.  Reference Intervals for Bone Histomorphometric Measurements Based on Data from Healthy Premenopausal Women.

Authors:  Shijing Qiu; George Divine; Elizabeth Warner; Sudhaker D Rao
Journal:  Calcif Tissue Int       Date:  2020-08-20       Impact factor: 4.333

9.  Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

Authors:  Danielle E Robinson; M Sanni Ali; Victoria Y Strauss; Leena Elhussein; Bo Abrahamsen; Nigel K Arden; Yoav Ben-Shlomo; Fergus Caskey; Cyrus Cooper; Daniel Dedman; Antonella Delmestri; Andrew Judge; Muhammad Kassim Javaid; Daniel Prieto-Alhambra
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

10.  Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report.

Authors:  Motoyuki Tanaka; Takao Setoguchi; Yasuhiro Ishidou; Yoshiya Arishima; Masataka Hirotsu; Yoshinobu Saitoh; Shunsuke Nakamura; Hironori Kakoi; Satoshi Nagano; Masahiro Yokouchi; Junichi Kamizono; Setsuro Komiya
Journal:  Diagn Pathol       Date:  2012-08-20       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.